Shanghai Helioson Pharmaceutical Co. Ltd. has patented molecular glue degraders comprising cereblon (CRBN) binding agents acting as proto-oncogene Vav (VAV1) degradation inducers found to be potentially useful for the treatment of autoimmune disease and cancer.
CD45RC is an isoform of protein tyrosine phosphatase receptor type C, a protein that plays a key role in regulating antigen receptor signaling in T and B cells. While it is expressed on most circulating B cells, it is only highly expressed on Th1 precursors, Th1 cells and T effector memory CD45RA+ cells (TEMRA).
Therorna Shanghai Co. Ltd. has presented data on TI-0032, an anti-CD19 CAR circular RNA therapeutic delivered by lipid nanoparticles (LNPs) for the treatment of autoimmune and hematological disorders.
Antengene Corp. Ltd. has obtained IND approval from China’s National Medical Products Administration (NMPA) for ATG-201 for the treatment of B-cell related autoimmune diseases.
Kymera Therapeutics has developed KT-579, a potent and selective IRF5 degrader as a novel approach for treating systemic lupus erythematosus (SLE) and Sjögren disease.
Researchers at Obleno Bio Inc. have reported preclinical efficacy data for LBL-051-S3, a trispecific T-cell engager antibody targeting CD3, CD19 and BCMA, in nonhuman primate models.
At the recent European Congress of Rheumatology (EULAR) meeting in London, researchers from Antegene Corp. Ltd. presented the preclinical characterization of ATG-207, an αCD3-TGF-β bifunctional fusion protein, in models of T-cell-driven autoimmune disease.
Systemic lupus erythematosus (SLE) is a chronic autoimmune disorder characterized by dysregulation in humoral immunity and sustained activation of B cells and autoantibody release, where BAFF (B-cell activating factor) and APRIL (a proliferation-inducing ligand) play crucial roles in B-cell differentiation and survival. Genescience Pharmaceutical Co. Ltd. has released data for its dual BAFF and APRIL inhibitor Gensci-136 for the treatment of SLE.
Modulating G protein-coupled receptors (GPCRs) is one of the major challenges in biomedicine. These are flexible proteins with small, deep binding pockets. The scientific community has explored small molecules, antibodies and nanobodies to develop ligands. Skape Bio Inc. is betting on creating miniproteins, a strategy that brings precise solutions for different functions.
Genome-wide association studies (GWAS) have identified multiple loci associated with complex diseases, but these are mostly on regulatory genes in the non-coding part of the genome and it has proved difficult to identify the effector genes that they control. Now, researchers in the U.K. have shown how single cell sequencing at scale can be used to precisely link non-coding GWAS loci to specific protein coding genes and cell types.
RSS
